Literature DB >> 28929282

Anoperineal lesions in Crohn's disease: French recommendations for clinical practice.

D Bouchard1, L Abramowitz2, G Bouguen3, C Brochard3, A Dabadie4, V de Parades5, M Eléouet-Kaplan6, N Fathallah5, J-L Faucheron7, L Maggiori8, Y Panis8, F Pigot6, P Rouméguère9, A Sénéjoux10, L Siproudhis3,11, G Staumont12, J-M Suduca12, B Vinson-Bonnet13, J-D Zeitoun14.   

Abstract

BACKGROUND: Anoperineal lesion (APL) occurrence is a significant event in the evolution of Crohn's disease (CD). Management should involve a multidisciplinary approach combining the knowledge of the gastroenterologist, the colorectal surgeon and the radiologist who have appropriate experience in this area. Given the low level of evidence of available medical and surgical strategies, the aim of this work was to establish a French expert consensus on management of anal Crohn's disease. These recommendations were led under the aegis of the Société Nationale Française de Colo-Proctologie (SNFCP). They report a consensus on the management of perianal Crohn's disease lesions, including fistulas, ulceration and anorectal stenosis and propose an appropriate treatment strategy, as well as sphincter-preserving and multidisciplinary management.
METHODOLOGY: A panel of French gastroenterologists and colorectal surgeons with expertise in inflammatory bowel diseases reviewed the literature in order to provide practical management pathways for perianal CD. Analysis of the literature was made according to the recommendations of the Haute Autorité de Santé (HAS) to establish a level of proof for each publication and then to propose a rank of recommendation. When lack of factual data precluded ranking according to the HAS, proposals based on expert opinion were written. Therefore, once all the authors agreed on a consensual statement, it was then submitted to all the members of the SNFCP. As initial literature review stopped in December 2014, more recent European or international guidelines have been published since and were included in the analysis.
RESULTS: MRI is recommended for complex secondary lesions, particularly after failure of previous medical and/or surgical treatments. For severe anal ulceration in Crohn's disease, maximal medical treatment with anti-TNF agent is recommended. After prolonged drainage of simple anal fistula by a flexible elastic loop or loosely tied seton, and after obtaining luminal and perineal remission by immunosuppressive therapy and/or anti-TNF agents, the surgical treatment options to be discussed are simple seton removal or injection of the fistula tract with biological glue. After prolonged loose-seton drainage of the complex anal fistula in Crohn's disease, and after obtaining luminal and perineal remission with anti-TNF ± immunosuppressive therapy, surgical treatment options are simple removal of seton and rectal advancement flap. Colostomy is indicated as a last option for severe APL, possibly associated with a proctectomy if there is refractory rectal involvement after failure of other medical and surgical treatments. The evaluation of anorectal stenosis of Crohn's disease (ARSCD) requires a physical examination, sometimes under anesthesia, plus endoscopy with biopsies and MRI to describe the stenosis itself, to identify associated inflammatory, infectious or dysplastic lesions, and to search for injury or fibrosis of the sphincter. Therapeutic strategy for ARSCD requires medical-surgical cooperation.

Entities:  

Keywords:  Abscess; Anal fistulas; Anal stenosis; Anoperineal lesions; Crohn’s disease; Guidelines; Recommendations

Mesh:

Substances:

Year:  2017        PMID: 28929282     DOI: 10.1007/s10151-017-1684-y

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  62 in total

Review 1.  AGA technical review on perianal Crohn's disease.

Authors:  William J Sandborn; Victor W Fazio; Brian G Feagan; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

2.  Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed?

Authors:  Shinnosuke Tanaka; Katsuichi Matsuo; Takamitsu Sasaki; Masahiko Nakano; Koutarou Sakai; Richiko Beppu; Yuichi Yamashita; Kazuhiro Maeda; Kunihiko Aoyagi
Journal:  Hepatogastroenterology       Date:  2010 Jan-Feb

3.  Operative results and quality of life after gracilis muscle transposition for recurrent rectovaginal fistula.

Authors:  J H Lefèvre; F Bretagnol; L Maggiori; A Alves; M Ferron; Y Panis
Journal:  Dis Colon Rectum       Date:  2009-07       Impact factor: 4.585

4.  [Infliximab therapy for Crohn's disease anoperineal lesions].

Authors:  A Ouraghi; S Nieuviarts; J L Mougenel; M Allez; M Barthet; F Carbonnel; J Cosnes; J P Gendre; B Flourié; J J Meurisse; P Quandalle; O Ernst; M Lemann; A Cortot; R Modigliani; J F Colombel
Journal:  Gastroenterol Clin Biol       Date:  2001-11

5.  European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease.

Authors:  Florian Rieder; Giovanni Latella; Fernando Magro; Elif S Yuksel; Peter D R Higgins; Antonio Di Sabatino; Jessica R de Bruyn; Jordi Rimola; Jorge Brito; Dominik Bettenworth; Gert van Assche; Willem Bemelman; Andre d'Hoore; Gianluca Pellino; Axel U Dignass
Journal:  J Crohns Colitis       Date:  2016-02-29       Impact factor: 9.071

6.  Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease.

Authors:  Jean-Charles Grimaud; Nicolas Munoz-Bongrand; Laurent Siproudhis; Laurent Abramowitz; Agnès Sénéjoux; Véronique Vitton; Luc Gambiez; Bernard Flourié; Xavier Hébuterne; Edouard Louis; Benoit Coffin; Vincent De Parades; Guillaume Savoye; Jean-Claude Soulé; Yoram Bouhnik; Jean-Frédéric Colombel; Jean-François Contou; Yves François; Jean-Yves Mary; Marc Lémann
Journal:  Gastroenterology       Date:  2010-02-20       Impact factor: 22.682

7.  Treatment of anovaginal or rectovaginal fistulas with modified Martius graft.

Authors:  K Songne; M Scotté; J Lubrano; E Huet; B Lefébure; Y Surlemont; S Leroy; F Michot; P Ténière
Journal:  Colorectal Dis       Date:  2007-09       Impact factor: 3.788

8.  Management of perianal Crohn's disease. Results of a multicenter study in Italy.

Authors:  M Pescatori; A Interisano; L Basso; F Arcanà; P Buffatti; F Di Bella; A Doldi; V Forcheri; R Gaetini; A Pera
Journal:  Dis Colon Rectum       Date:  1995-02       Impact factor: 4.585

9.  Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group.

Authors:  E J Irvine
Journal:  J Clin Gastroenterol       Date:  1995-01       Impact factor: 3.062

10.  A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn's disease.

Authors:  Daniel S Gingold; Zuri A Murrell; Phillip R Fleshner
Journal:  Ann Surg       Date:  2014-12       Impact factor: 12.969

View more
  9 in total

Review 1.  Management of anoperineal lesions in Crohn's disease: a French National Society of Coloproctology national consensus.

Authors:  D Bouchard; F Pigot; G Staumont; L Siproudhis; L Abramowitz; P Benfredj; C Brochard; N Fathallah; J-L Faucheron; T Higuero; Y Panis; V de Parades; B Vinson-Bonnet; D Laharie
Journal:  Tech Coloproctol       Date:  2019-01-02       Impact factor: 3.781

Review 2.  Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease.

Authors:  G Pellino; D S Keller; G M Sampietro; I Angriman; M Carvello; V Celentano; F Colombo; F Di Candido; S Laureti; G Luglio; G Poggioli; M Rottoli; S Scaringi; G Sciaudone; G Sica; L Sofo; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-03-14       Impact factor: 3.781

Review 3.  The Optimal Management of Fistulizing Crohn's Disease: Evidence beyond Randomized Clinical Trials.

Authors:  Panu Wetwittayakhlang; Alex Al Khoury; Gustavo Drügg Hahn; Peter Laszlo Lakatos
Journal:  J Clin Med       Date:  2022-05-28       Impact factor: 4.964

4.  Perianal Fistulas in Patients With Crohn's Disease, Part 2: Surgical, Endoscopic, and Future Therapies.

Authors:  Stephanie L Gold; Shirley Cohen-Mekelburg; Yecheskel Schneider; Adam Steinlauf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-09

5.  Contemporary surgical practice in the management of anal fistula: results from an international survey.

Authors:  C Ratto; U Grossi; F Litta; G L Di Tanna; A Parello; V De Simone; P Tozer; D DE Zimmerman; Y Maeda
Journal:  Tech Coloproctol       Date:  2019-07-31       Impact factor: 3.781

6.  Analysis of Risk Factors for Anorectal Stenosis of Perianal Fistulizing Crohn's Disease.

Authors:  MinMin Xu; BoLin Yang; HongJin Chen; YunFei Gu; YouRan Li
Journal:  Med Sci Monit       Date:  2020-02-28

7.  Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional study.

Authors:  Laura Sirmai; Anne-Laure Pelletier; Nathalie Gault; Camille Zallot; Guillaume Bouguen; Dominique Bouchard; Pascale Roland Nicaise; Marine Peyneau; Sandrine Sironneau; Marcelo De Carvalho Bittencourt; Antoine Petitcollin; Pedro Fernandez; Xavier Roblin; Laurent Siproudhis; Laurent Abramowitz
Journal:  World J Gastroenterol       Date:  2022-03-07       Impact factor: 5.742

8.  A Preclinical Validation of Iron Oxide Nanoparticles for Treatment of Perianal Fistulizing Crohn's Disease.

Authors:  Antoine Cazelles; Maxime K Collard; Yoann Lalatonne; Sabrina Doblas; Magaly Zappa; Camélia Labiad; Dominique Cazals-Hatem; Léon Maggiori; Xavier Treton; Yves Panis; Ulrich Jarry; Thomas Desvallées; Pierre-Antoine Eliat; Raphaël Pineau; Laurence Motte; Didier Letourneur; Teresa Simon-Yarza; Eric Ogier-Denis
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

9.  Ambulatory Surgery for Perianal Crohn's Disease: Study of Feasibility.

Authors:  S Sibio; A Di Giorgio; M Campanelli; S Di Carlo; A Divizia; C Fiorani; R Scaramuzzo; C Arcudi; G Del Vecchio Blanco; L Biancone; G Sica
Journal:  Gastroenterol Res Pract       Date:  2018-12-23       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.